The company has not filed an annual or quarterly report since its Q3 FY2021 10-Q, filed Nov 4, 2021. Its latest SEC filing is a SC 13G/A from Feb 14, 2022.
10-Q for Q3 FY2021, filed Nov 4, 2021
The sections below describe the company as of the FY2020 annual report.
Develops drug candidates for immune and fibrotic diseases and cancer, and sells CLOVIQUE through specialty pharmacies and distributors.
10-K for FY2020, filed Mar 4, 2021We are a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs.…View ↗
Immuno-oncology. We have a biologics research platform focused on the development of immuno-oncology therapeutics, specifically…View ↗
Kadmon Pharmaceuticals is our wholly owned, fully integrated commercial operation. Although our commercial business generates revenue, we…View ↗
Our commercial organization encompasses managed care and specialty pharmacy account directors, experienced regulatory, quality, compliance…View ↗
Our revenue is derived from sales of CLOVIQUE™ (Trientine Hydrocholride), licensing revenue related to our strategic partnerships, and…View ↗
CLOVIQUE buyers pay within 30 days of shipment; license partners pay under contract schedules, including upfront fees and milestone or other contingent payments; sublease revenue comes from services as they are provided.
10-K for FY2020, filed Mar 4, 2021These contracts typically include a single promise to deliver a fixed amount of product to the customer with payment due within 30 days of…View ↗
The terms of these license agreements typically may include payment to the Company of one or more of the following: nonrefundable, up-front…View ↗
The Company receives payments from its licensees based on schedules established in each contract. Upfront payments and fees are recorded as…View ↗
The other revenue generated by the Company is primarily related to a sublease agreement with MeiraGTx (Note 10). The Company recognizes…View ↗
10-K for FY2020, filed Mar 4, 2021
FY2020 revenue by product or service ↗$8.3M
10-K for FY2020, filed Mar 4, 2021
$8.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net Sales
Sold outright
10-K for FY2020, filed Mar 4, 2021 |
20%
FY2017: 43%
|
Net Sales, FY2020
$1.7M Sources
|
Sold outright |
|
License Revenue
Licensed
10-K for FY2020, filed Mar 4, 2021 |
72% |
License Revenue, FY2020
$6M Sources
|
Licensed |
|
Other Revenue
Recurring
|
7.5% |
Other Revenue, FY2020
$623K Sources
|
Recurring |
Kadmon planned a direct U.S. commercial effort aimed at treating specialists and payors for belumosudil, with products distributed through independent specialty pharmacies and distributors.
10-K for FY2020, filed Mar 4, 2021
No. It lost $108.9M in FY2020.
10-Q for Q3 FY2021, filed Nov 4, 2021
−$33MView ↗
8-K, filed Nov 9, 2021
Shareholders of Kadmon common stock voted to approve the acquisition at a special meeting of stockholders on November 5, 2021 and will…View ↗
8-K, filed Jul 19, 2021
NEW YORK, July 16, 2021 – Kadmon Holdings, Inc. (Nasdaq: KDMN) today announced that the U.S. Food and Drug Administration (FDA) has…View ↗
Shrank. Revenue fell 68% in 4 years, from $26.1M in FY2016 to $8.3M in FY2020, about 25% a year.
Commercial product sales
The earlier report described trientine hydrochloride formulations as candidates awaiting approval; the latest report says CLOVIQUE sales generated revenue.
10-K for FY2017, filed Mar 6, 2018 10-K for FY2020, filed Mar 4, 2021KD034. We are developing a portfolio of generic formulations of trientine hydrochloride called KD034 for the treatment of Wilson’s disease…View ↗
Our revenue is derived from sales of CLOVIQUE™ (Trientine Hydrocholride), licensing revenue related to our strategic partnerships, and…View ↗
Loading...
